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Abstract FimH-mediated adhesion of Escherichia coli to
bladder epithelium is a prerequisite for urinary tract infections.
FimH is also essential for blood-borne bacterial dissemina-
tion, but the mechanisms are poorly understood. The purpose
of this study was to assess the influence of different FimH
mutations on bacterial adhesion using a novel adhesion assay,
which models the physiological flow conditions bacteria are
exposed to. We introduced 12 different point mutations in the
mannose binding pocket of FimH in an E. coli strain express-
ing type 1 fimbriae only (MSC95-FimH). We compared the
bacterial adhesion of each mutant across several commonly
used adhesion assays, including agglutination of yeast, adhe-
sion to mono- and tri-mannosylated substrates, and static ad-
hesion to bladder epithelial and endothelial cells. We per-
formed a comparison of these assays to a novel method that
we developed to study bacterial adhesion to mammalian cells
under flow conditions. We showed that E. coliMSC95-FimH
adheres more efficiently to microvascular endothelium than to
bladder epithelium, and that only endothelium supports adhe-
sion at physiological shear stress. The results confirmed that
mannose binding pocket mutations abrogated adhesion. We
demonstrated that FimH residues E50 and T53 are crucial
for adhesion under flow conditions. The coating of endothelial
cells on biochips and modelling of physiological flow condi-
tions enabled us to identify FimH residues crucial for adhe-
sion. These results provide novel insights into screening
methods to determine the effect of FimH mutants and poten-
tially FimH antagonists.
Introduction
Infection with Escherichia coli is the most frequent cause
of septicaemia in humans and commonly originates from
the urinary tract [1]. Uropathogenic E. coli (UPEC) ad-
here to bladder epithelium in a process mediated by type 1
fimbriae via FimH engaging uroplakin 1a on urothelium,
leading to urinary tract infection [2, 3]. Subsequently,
FimH promotes invasion and is critical for blood-borne
dissemination to other tissues [4]. Thus, in neonatal men-
ingitis, FimH is essential for the localisation of UPEC to
brain microvascular endothelium and invasion of the me-
ninges [5, 6]. This establishes the pathogenic importance
of FimH-mediated adhesion beyond the urinary tract.
FimH is located at the tip of type 1 fimbriae expressed by
Gram-negative pathogens, including E. coli, Salmonella
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enterica and Klebsiella pneumoniae [7, 8]. It has two domains:
an N-terminal lectin domain of FimH containing the mannose
binding pocket (MBP) responsible for bacterial adhesion to
cellular ligands and a C-terminal pilin domain that connects
FimH to the fimbrial rod [9]. Introduction of shear stress after
initial binding induces allosteric interactions between the lectin
and pilin domains that increase the affinity of mannose for the
MBP through a catch bond mechanism [10, 11].
Over the past decade, mutated FimH have been used exten-
sively to probe the molecular basis for its binding to mannose,
most commonly in studies performed under static conditions
using yeast agglutination [12], FimH binding to pure mannose
substrates [7, 10] or bacterial adhesion to bladder carcinoma
cell lines [13] as end points. These have provided considerable
insights into the molecular basis for the MBP binding with
mannose, but necessarily poorly reflect physiological condi-
tions in which it normally takes place. Specifically, there is a
lack of data on FimH-dependent bacterial adhesion to micro-
vascular endothelium that is thought to underlie blood-borne
dissemination of E. coli [4]. We addressed this issue by gener-
ating and validating a panel of multiply disabled E. coli strains
that uniquely express type 1 fimbriae and normal or mutated
FimH [14], and systematically analysing the ability of the mu-
tant strains to adhere to microvascular endothelium and bladder
epithelium, under both static conditions and physiological
shear stress. We show that FimH-dependent adhesion to endo-
thelium occurs much more efficiently than to bladder epitheli-
um and identify MBP residues that are critical for adhesion
under shear stress but without detectable effects in static assays.
Our results characterise important differential effects of FimH-
mediated adhesion to different cellular substrates that reflect the
different physiological conditions they are exposed to in vivo.
Materials and methods
Chemicals
Alpha-D-mannopyranoside (mannoside), RNase B (tri-
mannosylated-3 M) and bovine serum albumin (BSA) were
from Sigma-Aldrich (St. Louis, MO, USA). D-Mannose-BSA
(mono-mannose-1 M) (14 atom spacer) was from Dextra
Laboratories (Reading, UK), and 0.05 % Trypsin-EDTA and
HEPES were from Life Technologies (Carlsbad, CA, USA).
Antibodies
The following polyclonal antibodies were used for
Western blot: uroplakin 1a (ABIN955479, 1:100, antibod-
ies-online, Atlanta, GA, USA) and beta-actin (A2066,
1:500, Sigma-Aldrich). Secondary antibodies conjugated
with alkaline phosphatase were from Promega (1:5000,
Madison, WI, USA).
Cell lines
Human dermal microvascular endothelial cells (G1S1) and
conditionally immortalised glomerular endothelial cells
(GEnC) were cultured using standard validated methods [15,
16]. GEnC were propagated at 33 °C (proliferation phase) and
differentiated at 37 °C for 5 days prior to each experiment
[15]. The human transitional cell carcinoma cell lines 5637
(ATCC HTB-9) and HT-1376 [17] and SV40-transformed
urothelial cell line SV-HUC [18] were all kind gifts from
Michael Wirth (University of Vienna).
Bacterial strains and GFP labelling of bacteria
Escherichia coliwere labelled with green fluorescence protein
(GFP) using phage 1 transduction of gfp:bla fromE. coli strain
OS56 into the multiply disabled E. coli MS528 (E. coli
MG1655 Δfim Δflu) [19], resulting in strain E. coli
MSC95. The gfp gene was inserted into the chromosome of
MS528 using the Lambda Red System with the lambda red
proteins encoded on the plasmid pTP223, which includes a
gene for tetracycline resistance [20, 21] (kindly provided by
Antony Poteete). As the source of the drug resistance cassette,
pKD4 carrying a kanamycin cassette was used [22].
Escherichia coliMSC95 completely devoid of all fimbriae
was used as the FimH-negative control strain. Escherichia coli
MSC95 expressing FimH (MSC95-FimH) was derived from
E. coli PC31 fimH [23] located on the pMAS4 plasmid, to-
gether with pPKL115 carrying the entire fim gene cluster with
a knock-out mutation in fimH [24] and used as standard
FimH-bearing control strain.
Site-directed mutagenesis of fimH
Mutations were introduced into the fimH gene from E. coli
PC31 carried by the pMAS4 plasmid [23] by site-directed
mutagenesis using the Phusion Site-Directed Mutagenesis
Kit (F-541, Thermo Scientific, Waltham, MA, USA), follow-
ing the manufacturer’s instructions. Specific primers were de-
signed for each desired point mutation. For the expression of
type 1 fimbriae carrying the mutated FimH protein, plasmids
carrying themutated fimH gene were individually transformed
intoMSC95 containing the plasmid pPKL115 carrying the fim
gene cluster with a knock-out mutation in fimH [24].
Recombinant strains were grown in LB medium supplement-
ed with 10 μg/ml chloramphenicol and 100 μg/ml ampicillin.
Yeast agglutination assay
The ability of the recombinant fimH mutant strains to express
a D-mannose binding phenotype was examined by yeast ag-
glutination using an established method [25]. Briefly, 20 μl of
1 % (v/w) yeast in PBS were mixed with 20 μl of serial
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dilutions (non-diluted up to 1:16) of bacterial suspensions in
PBS (normalised to OD600 = 0.3) of either MSC95-FimH or
mutant strains on a microscopy slide, and the dilution at which
agglutination occurred was recorded.
Bacterial adhesion under static conditions
GFP-expressing E. coli MSC95-FimH (4 × 106 CFU) were
incubated with confluent mammalian cell lines in 12-well cell
culture plates for 30 min on ice to prevent internalisation. The
cultures were then washed three times with PBS to remove
non-adherent bacteria before the mammalian cells were de-
tached with trypsin-EDTA and the resulting single-cell suspen-
sions were analysed by flow cytometry (LSRFortessa SORP,
Becton Dickinson, San José, CA, USA). Bacterial adherence
was quantified from the intensity of the GFP signal from single
endothelial or urothelial cells identified by forward/sideward
scatter, thus excluding GFP signals associated with cell clusters
and/or from free bacteria. The results were analysed with
FlowJo (Tree Star, Inc., Ashland, OR, USA) and expressed as
the adhesion index, defined as the percentage of GFP-positive
E. coli bound to mammalian cells. The adhesion of mutant
E. coli strains to the cell lines was expressed in the results as
a percentage of adhesion of the MSC95-FimH parent strain.
The mannose dependence of adhesion was assessed by
suspending the E. coli in media containing 4 % mannoside
for 10 min on ice before the experiment.
Bacterial adhesion under flow conditions
Vena8 Fluoro+ biochips (Cellix, Dublin, Ireland) were coated
overnight with either 200 μg/ml D-mannose-BSA (1 M),
100 μg/ml RNAse B with high 3-mannose (3 M) residues or
2 % BSA alone at 4 °C and blocked prior to use with PBS +
0.2 % BSA. A total of 1 × 106 E. coli prepared as described
above were added to the substrates. The biochips were set up
and washed according to the manufacturer’s instructions using
the VenaFlux Assay Software (Cellix). The specificity of
binding was assessed by pre-incubating E. coli MSC95-
FimH with 2 % mannoside in PBS for 10 min prior to the
experiment. Adhesion of bacteria under a shear stress of 1
dyne/cm2 was recorded every second in phase contrast and
the settings were equal for both 1 M and 3 M (exposure time
344 ms, magnification 20×) for 5 min using an Axiovert
200M microscope (Zeiss, Oberkochen, Germany) with
AxioVision 4.5 software. The total number of adherent bacte-
ria per high-power field (HPF) was counted manually using
ImageJ [26].
To assess FimH-dependent adhesion to mammalian cells
under flow conditions, Vena8 Endothelial 8-channel biochips
(Cellix), 800 nm long and 120 nm wide, were sterilised by
UV-light and coated with FNC coating buffer (AthenaES,
Baltimore, MD, USA) at 4 °C overnight. Cells were seeded
into the biochips at 5 × 105 cells per channel and allowed to
adhere for 1 h, resulting in confluent cell layers. The cells were
incubated for another 24 h in the biochip connected to the
Kima pump (Cellix) with the following shear stress condi-
tions: for bladder epithelial cells, 150 μl/min for 6 min,
followed by 20 min of absence of flow; for microvascular
endothelial cells, 450 μl/min for 6 min, followed by 20 min
of absence of flow. Both were incubated at 37 °C with 5 %
CO2. Bacterial samples were prepared as described for the
1 M and 3 M assays. The flow chamber was then connected
to the Mirus Evo Nanopump (Cellix) and the channels were
rinsed three times with 25 μl of media prior to each experi-
ment, and bacterial adhesion was initiated by the addition of 1
× 106 of bacterial suspension. As above, adhesion of bacteria
was recorded every second under a shear stress of 1 dyne/cm2
in phase contrast and the settings were equal in all conditions
(exposure time 344 ms, magnification 32×) for 5 min. In some
experiments (stop/flow), 1 dyne/cm2 was exerted and paused
for 5 min once bacteria were observed in the HPF, before 1
dyne/cm2 shear stress was re-applied. This, however, induced
some gaps between the cells; any E. coli adhering to this were
excluded, as mentioned above. The total numbers of E. coli
that were adherent were counted as above. Escherichia coli
were considered adherent when they were adhering for at least
five frames at the end of the 5 min. Excluding criteria were
E. coli that adhered to any plastic surface.
Transmission electron microscopy
Transmission electron microscopy (TEM) was performed to
confirm the expression of intact fimbriae on all mutant strains.
Five independent TEM micrographs (final magnification
60,000×) were analysed from each mutant strain and were
used to count the number of fimbriae along three circumfer-
ential areas of 500 nm each in which individual fimbriae were
clearly distinguishable. The total number of fimbriae was then
calculated from the circumferential outline of the bacteria
(∼4500 nm) using ImageJ.
Structural modelling
The crystal structure of FimH (PDB ID: 2VCO) [27] was
uploaded in Visual Molecular Dynamics [28] (VMD,
University of Illinois, Urbana–Champaign, IL, USA). The
residues that we experimentally tested were highlighted.
Statistical analyses
All calculations were made using GraphPad Prism 5.0
(GraphPad Prism Software, La Jolla, CA, USA) and p-values
<0.05 were considered significant. Absolute values for the
number of adherent bacteria were summarised as means ±
standard error of the mean (SEM) and the significance of
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differences between them was assessed by Student’s t-test.
Adhesion index assays were expressed as medians with inter-
quartile ranges and illustrated using box and whisker plots.
The overall significance was tested by Kruskal–Wallis follow-
ed by, when appropriate, individual two-tailed Mann–
Whitney tests. In both cases, individual pairwise p-values
were corrected for multiple comparisons using the
Benjamini–Hochberg method, with a false discovery rate of
α set to 0.05 [29]. For the correlation data, the average adhe-
sion of the mutant strains was analysed; MSC95-FimH and
MSC95 were excluded from the correlation calculations.
Results
Generation and characterisation of E. coli strains
expressing mutated FimH
Using MSC95-FimH as the parent strain [23], we generated a
panel of 14 GFP-tagged E. coli strains that uniquely express
type 1 fimbriae with different alanine point mutations in the
MBP of FimH (listed in Table 1). The residues that were se-
lected for mutation directly interact with mannose (N46, D47,
P49, D54, Q133, N135 and D140) and have been shown to
Table 1 Overview of the mutations generated in MSC95-FimH and adhesion to 1 M and 3 M
FimH E. coli PC31
MKRVITLFAVLLMGWSVNAWS
1      FACKTANGT AIPIGGGSAN VYVNLAPVVN VGQNLVVDLS TQIFCHNDYPE 50
51    TITDYVTLQR GSAYGGVLSN  FSGTVKYSGS  SYPFPTTSET  PRVVYNSRTD     100
101  KPWPVALYLT PVSSAGGVAI KAGSLIAVLI  LRQTNNYNSD DFQFVWNIYA 150
151  NNDVVVPTGG CDVSARDVTV TLPDYPGSVP IPLTVYCAKS QNLGYYLSGT      200
201 TADAGNSIFT NTASFSPAQG VGVQLTRNGT IIPANNTVSL  GAVGTSAVSL 250
251 GLTANYARTG GQVTAGNVQS  IIGVTFVYQ                                                              279
Mutant strain yeast agglutination 1M (#) 1M (norm %) 3M (#) 3M (norm %)
MSC95-FimH 1:4 21.7±2.4 100 20.6±2.0 100
MSC95 NA 0 0 0 0
N46A* NA 0.3±0.3 1 (0-2) 6.0±1.0 11 (2-21)
D47A* 1 0 0 0 0
P49A* NA 0 0 0 0
E50A 1 6.4±2.5 34 (11-55) 8.2±1.7 56 (19-74)
T53A 1:2 14.1±4.4 58 (12-115) 16.6±4.3 68 (23-85)
D54A NA 0 0 0 0
Y55A 1:2 8.7±3.1 17 (10-24) 12.3±4.4 38 (0-78)
V56A 1:2 11.3±4.0 44 (0-64) 9.5±0.9 65 (65-67)
T57A 1 4.0±1.7 15 (12-33) 7.8±3.1 14 (12-48)
Q133A 1 0 0 0.5±0.5 3 (0-6)
N135A 1 0 1 (0-2) 2.5±0.3 0
D140A 1 0.3±0.2 2 (0-4) 1.5±1.5 0
The ability of E. coli FimHmutants to adhere to mannose substrates under flow and to agglutinate yeast. Binding properties were comparable in all three
assays; however, some mutants exhibited marked differences in their ability to bind either 1 M or 3 M. Titres for yeast agglutination was the highest
dilution at which agglutination still occurred. The adhesion of mutant E. coli to 1 M and 3 M was assessed, and the raw numbers of binding E. coliwere
normalised (norm) against E. coli numbers obtained in the same experiment with MSC95-FimH. Data represent mean % (range: lower limit %–upper
limit %,). MBP: Mannose binding pocket; 1 M: D-mannose-BSA; 3 M: RNase containing 3-mannose residues; NA: no agglutination. An asterisk (*)
indicates that the strains had dysmorphic fimbriae
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bind to bladder tissue [27, 30, 31]. Two other residues (E50 and
T53) were characterised in their ability to agglutinate yeast [32]
and were included to examine their influence on MBP–man-
nose interactions. Three further residues are located at the back
of the MBP, but their influence on adhesion was only analysed
regarding mannose binding (Y55 and T57 [32]) or not at all
(V56). The use of this panel of FimH mutations allowed us to
systemically analyse the influence of each residue on adhesion
to mammalian cells and binding to mannosylated substrates,
and relate our results to previous findings.
Since FimH mutations can disrupt fimbriogenesis [33], we
assessed the integrity of the fimbriae of the mutant FimH strains
by electron microscopy. Three strains had reduced numbers of
dysmorphic fimbriae (N46A, D47A and P49A) and were ex-
cluded from further analysis. The remaining nine mutant strains
had quantitatively and qualitatively normal fimbriae when com-
pared to the parental MSC95-FimH strain (one-way ANOVA
p = 0.24) (Fig. 1) and were used to analyse bacterial adhesion to
yeast, to biochemical substrates and to mammalian cells.
FimH-dependent bacterial adhesion to 1 M and 3 M
First, we tested FimH function by the established yeast agglu-
tination assay, which provides a swift but semi-quantitative
assessment [12, 34]. While D54A did not bind yeast, weak
agglutination was observed for E50A, T57A, Q133A and
N135A. The mutants T53A, Y55A and V56A adhered yeast
with moderate titres, when compared to the native FimH bear-
ing strain MSC95-FimH (Table 1). MSC95 lacking fimbriae
did not cause yeast agglutination. The mutants analysed here
have different yeast agglutination patterns, but do not necessar-
ily reflect in vivo conditions [35].
Next, we quantified FimH-mediated adherence to
mannosylated substrates under flow conditions [10] that should
better reflect physiological conditions in vivo. Binding to
mono-mannosylated (1M) proteins is crucial for uropathogenic
E. coli, while binding to tri-mannosylated (3 M) proteins has
been reported to be important for non-uropathogenic E. coli for
colonisation elsewhere [36, 37]. The MSC95-FimH parental
strain showed strong adherence to yeast and efficiently bound
to the 1 M substrate, D-mannose-BSA (21.7 ± 2.4 bacteria/
HPF), and to the 3 M substrate, RNase B (20.6 ± 2.0 bacteria/
HPF). The MBP mutations showed abrogated adhesion to 1 M
(range 0–58 %) and 3 M (range 0–68 %) compared to the
parent strain MSC95-FimH (Fig. 2). The results of two tests
correlated in five of the nine strains tested: E50A and T53A
bound moderately to yeast and to both 1 M [34 % (11–55 %)
and 58 % (12–115 %) of MSC95-FimH binding, respectively]
Fig. 1 Characterisation of FimH
mutant strains. a Representative
images of the different mutants
expressing type 1 fimbriae. b The
number of fimbriae around the
circumference of the parent strain
MSC95-FimH was 110.7 ± 22.1.
None of the numbers of fimbriae
in the remaining mutant strains
differed significantly from the
parent strain (one-way ANOVA
p = 0.16, drawn from the same
population). The graph is
representative of three
independent experiments. The
fimbriae of five different bacteria
were counted per strain. Data are
shown as mean ± standard error of
the mean (SEM). ND not done
Eur J Clin Microbiol Infect Dis
and 3 M [56 % (19–74 %) and 68 % (23–85 %)] (Table 1). In
contrast, D54A did not agglutinate yeast nor did it bind to 1 M
or 3 M. Mutant D140 was able to weakly agglutinate yeast but
did not bind to 1M [2 % (0–4 %)] or 3 M (0 %). Mutant Y55A
agglutinated yeast but was severely impaired in binding to both
1 M [17 % (10–24 %)] and 3 M [38 % (0–78 %)] (Table 1).
V56A, Q133A and N135A weakly agglutinated yeast but
showed either moderate binding to 1 M [V56A; 44 % (0–
64 %)] or none [Q133A; 0 % and N135A; 1 % (0–2 %)], with
similar binding to 3M [65% (65–67%), 3% (0–6%) and 0%,
respectively]. Mutant strains with dysmorphic fimbriae did not
bind to 1M or 3M and did not agglutinate yeast (N46A, P49A)
or only weakly (D47A) (Table 1).
FimH-dependent bacterial adhesion to cells under static
conditions
We analysed the effect of different FimH mutations on
adhesion to the relevant cell types by adapting the
standard flow cytometry-based bacterial adhesion assay
performed under static conditions [38]. FimH-dependent
adhesion of GFP-tagged E. coli was quantified using an
adhesion index calculated from the percentage of mam-
malian cells with adherent bacteria (Fig. 3a). Multiply-
disabled MSC95-FimH adhered significantly better to en-
dothelium derived from skin (G1S1) or glomeruli (GEnC)
[G1S1; adhesion index 57.3 %, interquartile range (IQR)
51.9–71.4; GEnC; 55.2 % (IQR 40.2–63.9)] than to blad-
der urothelial cell lines, derived from normal bladder (SV-
HUC; 37.3 %; IQR 26.5–57.6, p < 0.001 to G1S1, p < 0.01
to GEnC) or bladder carcinomas (5637 cells; 11.6 %; IQR
6.7–27.5, p < 0.01 to GEnC and HT-1376; 20.2 %; IQR
16.3–22.4, p < 0.01 to GEnC). Adhesion was both FimH-
and mannose-dependent because it did not occur in the ab-
sence of FimH expression and was abrogated by pre-
incubation with 4 % mannoside (Fig. 3b). Despite the
strong expression of uroplakin 1a, the primary receptor
for FimH on urothelium (Fig. S1), adhesion to urothelial
Fig. 2 Mutations in FimH alter adhesion to 1 M-BSA and 3 M (RNAse
B) under shear stress conditions. a The location of the mutations in this
study are depicted in this crystal structure of lectin domain FimH (PDB
entry: 2VCO). The different mutants were in the mannose binding pocket
(purple) and in the flanking region (teal). Other functional FimH regions
are tyrosine gate (green) and the hydrophobic ridge (yellow). b, c The
binding of MSC95-FimH mutant strains to D-mannose-BSA (1 M, white
bars) and RNase B containing 3-mannose residues (3 M, black bars) was
determined under shear stress conditions. Adhesion of bacteria under a
shear stress of 1 dyne/cm2 was recorded every second in phase contrast
for 5 min with equal settings for both 1 M and 3 M, and the total number
of adherent bacteria per high power field (HPF) was counted. Mutations
in the mannose binding pocket of FimH resulted in profound differences
of adhesion when compared to MSC95-FimH. The bars represent the
mean percentage of adhesion of the different mutations compared to
MSC95-FimH (100 %) ± range (min–max). Each strain was analysed at
least three times in triplicate. NO no binding observed
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cells was significantly less than to endothelial cells. To deter-
mine if the differences remained under physiological condi-
tions, we analysed the adhesion of MSC95-FimH to urothelial
and endothelial cells under flow.
FimH-dependent bacterial adhesion under shear stress
conditions
Blood-borne bacteria encounter endothelium under shear
stress, estimated to be around 1 dyne/cm2 in both glomerular
and dermal capillaries [39, 40]. At this rate of flow, MSC95-
FimH adhered effectively to confluent monolayers of G1S1
and GEnC in microfluidic flow chambers (G1S1: 12.6 ± 4.4
bacteria/HPF, GEnC: 10.2 ± 2.7) (Fig. 4a, b). Adhesion oc-
curred rapidly without the rolling behaviour that is character-
istic of leukocyte adhesion and, once adherent, the bacteria did
not detach. Again, adhesion was entirely FimH- andmannose-
dependent (data not shown and Fig. 4a). Unexpectedly,
MSC95-FimH did not adhere to any of the bladder cell lines
under shear stress (Fig. 4a, b). To stimulate the conditions of
bladder voiding, we allowed MSC95-FimH to adhere for
5 min under static conditions before applying flow (stop/flow
assay). MSC95-FimH adhered effectively under static condi-
tions and was not dislodged from either bladder or endothelial
cells by subsequent flow conditions, up to 15 dyne/cm2 (data
not shown), but MSC95-FimH still adhered more efficiently
to GEnC in this assay (GEnC: 38.0 bacteria/HPF; SV-HUC:
5.9; 5637 cells: 2.5; and HT-1376 cells: 4.4) (Fig. 4c).
Adhesion ofmutant FimH tomammalian cells under static
and shear stress conditions
We then measured the ability of the FimH mutant strains to
adhere to SV-HUC and GEnC in our static adhesion assay.
Seven of the strains (MSC95, D54A, Y55A, T57A, Q133A,
N135A and D140A) adhered less well, between 0 and 31.3 %
of MSC95-FimH, to GEnC and SV-HUC (Fig. 5a). By con-
trast, alanine substitution of E50 and T53 had little or no effect
(Fig. 5a) and adhesion to both cell lines was inhibited by
mannoside, excluding the acquisition of novel mannose-
Fig. 3 Adhesion of MSC95-
FimH to cells under static condi-
tions. a FACS analysis demon-
strates that GFP-labelled FimH-
positive E. coli (MSC95-FimH)
adhere to the normal bladder epi-
thelial cell line SV-HUC under
static conditions (appearance of
GFP positive peak, left panel),
while FimH-negative E. coli
(MSC95) (absence of GFP posi-
tive peak, middle panel) do not.
Right panel SV-HUC alone. b
MSC95-FimH (white boxes,
FimH+) adhere better to human
dermal microvascular (G1S1) and
immortalised glomerular endo-
thelial cells (GEnC) as analysed
by FACS than to SV-HUC, and
only poorly to malignant
urothelial cells (5637 and HT-
1376). MSC95 (FimH-negative)
confirms that adherence is FimH-
dependent. *p < 0.05, **p < 0.01,
Kruskal–Wallis test followed by
two-tailed Mann–Whitney test.
Adhesion was determined to each
cell line in at least four experi-
ments in triplicate
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independent binding sites as an explanation (Fig. S2). The
remaining mutant strain V56A showed partial [63 % (55–
71 %)] adhesion compared to the MSC95-FimH to GEnC,
but this was also not due to mannose-independent binding
(Fig. 5a and S2).
The effect of MBP mutations was even more pronounced
under shear stress. Alanine substitution abrogated adhesion to
GEnC in all mutant strains (Fig. 5b). Remarkably, the E50A and
T53Amutants adhered normally under static conditions but had
over 90 % reduced adhesion under shear stress (0.6 ± 0.3 and
0.5 ± 0.2 bacteria/HPF, respectively) compared to 8.5 ± 1.9 of
MSC95-FimH (both p < 0.001, Student’s t-test). Only V56A
that retained 63 % of its adhesive properties to GEnC under
static conditions also adhered to these cells under flow [3.6 ±
0.5 bacteria/HPF (p = 0.08)] or 42% ofMSC95-FimH (Fig. 5b).
MSC95-FimH did not adhere to SV-HUC under shear
stress and, so, we used the stop/flow assay to compare the
adhesion of the mutants. Again, most strains did not adhere
in this condition (Fig. S3). E50A and T53A mutants that ad-
hered normally under static conditions exhibited around 50 %
reduced adhesion (3.5 ± 1.5 and 6.0 ± 1.0 bacteria/HPF, re-
spectively) compared to 8.8 ± 1.1 of MSC95-FimH. The only
mutant strain not affected was V56A, which adhered more
effectively than the parent strain (14.0 ± 1.0).
Fig. 4 Adhesion of MSC95-FimH to cells under shear stress conditions.
aMSC95-FimH (white bars) adhere to endothelial but not urothelial cells
under shear stress conditions. More E. coli adhere to glomerular endothe-
lial cells (GEnC) when compared to urothelial cells (SV-HUC). Data are
shown as mean ± SEM. ND = no binding detected. *p < 0.05,
***p < 0.001. b Adhesion of bacteria under a shear stress of 1 dyne/cm2
was recorded every second in phase contrast for 5 min with equal settings
for GEnC (top) and SV-HUC (bottom), and the total number of adherent
bacteria per high power field (HPF) was counted. Adhesion to each cell
line was determined in at least four experiments in triplicate. c
Five minutes of static conditions followed by flow (stop/flow assay)
allowed MSC95-FimH (white bars) to adhere to benign (SV-HUC) and
malignant urothelial cells (5637, HT-1376). Data are shown as mean
± SEM. ***p < 0.001. Adhesion is mannose-dependent both under
shear stress (a) and depends on FimHpresence in stop/flow conditions (b)
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Correlation between FimH mutant strains analysed
with different methods
The correlation of the FimH mutants (Fig. S4) between adhe-
sion to 1 M and the static adhesion to cells was 0.96 for GEnC
and 0.75 for SV-HUC (Spearman, p = 0.0002 and p = 0.026,
respectively). Between static adhesion and to 3 M, the corre-
lation was similar; 0.84 for GEnC and 0.64 for SV-HUC (p =
0.006 and p = 0.066, respectively). The correlation of the mu-
tant strains between adhering under static or shear stress con-
ditions to GEnC was 0.59 (p = 0.097). The correlation for the
different mutants to GEnC under flow was equal for both 1 M
and 3 M; 0.71 for 1 M and 0.72 for 3 M (both p = 0.037). The
adhesion of the mutants to SV-HUC in the stop/flow assay
correlated well with adhesion to GEnC under continuous
flow; 0.76 (p = 0.021) but less with adhesion under static con-
ditions to SV-HUC; 0.55 (p = 0.133). Finally, the correlation
between adhesion to 1 M and 3 M was 0.90 (p = 0.0020).
Thus, there is a strong correlation between the adhesion on
mannosylated substrates and static adhesion to cells.
However, the more stringent conditions of adhesion under
flow revealed stronger effects of FimH mutations that were
masked when adhesion was analysed under static conditions.
The results demonstrate the critical influence ofMBP residues
on bacterial adhesion to endothelium under shear stress con-
ditions, even if there is a high correlation between SV-HUC
and GEnC; 0.91 (p = 0.0013) (Fig. S4). They also show that
binding to mannosylated substrates is not a true reflection of
the effect of FimH mutations. Therefore, an assay in which
cells are usedmimicking the physiological conditions encoun-
tered in vivo is more informative and provides additional in-
sight into the adhesive properties of FimH variants.
Discussion
Type 1 fimbriated pathogens, like E. coli, adhere to a variety
of biological surfaces, both epithelia and endothelia.
Fig. 5 FimH mutations influence adhesion to endothelial and urothelial
cells under static and shear stress conditions. a Adhesion of MSC95-
FimH and nine FimH strains with mutations in the MBP was analysed
under static conditions followed by FACS to glomerular endothelial
(GEnC, white bars) and urothelial cells (SV-HUC, black bars).
Mutations show abrogated binding, similar in both endothelial and
urothelial cells. Data are shown as the average measurements of two
individual experiments done in triplicate with the mean. *p < 0.05,
**p < 0.01 compared to MSC95-FimH (Kruskal–Wallis followed by
Mann–Whitney tests). Each strain was analysed two times in triplicate
and individual p-values were corrected by the Benjamini method. b The
amount of MSC95-FimH and FimHmutant E. coli strains that adhered to
glomerular endothelial cells (GEnC) per HPF was counted after 5 min of
shear stress. Data are shown as mean ± SEM. *p < 0.05, **p < 0.01
compared to MSC95-FimH (Student’s t-test). NO no binding observed.
Each strain was analysed three times in triplicate
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Accordingly, they have adapted by modifying the sequence
and structure of adhesins like FimH to enable improved adhe-
sion under different—static or shear stress—conditions [10,
41]. Our study explores the methodologies used to analyse
FimH-mediated adhesion of E. coli using mutations in the
MBP of FimH [31]. We first used yeast agglutination as an
established screening assay [34] to test the functionality of
mutant FimH and found that, to a varying degree, all our
mutant strains were able to adhere to yeast. These results were
comparable to those obtained with the more physiological
binding to mannosylated substrates and mammalian cells un-
der both static and shear stress conditions, which confirmed
that three mutant strains lacking intact fimbriae were unable to
adhere. All our strains were engineered to bear type 1 fimbriae
only and the differences observed in these assays cannot be
attributed to other pili, whose possible influence remains enig-
matic. They confirm, however, the necessity for additional
investigations to establish the adhesive properties of
(mutant) FimH. The analysis of FimH-mediated adhesion un-
der flow to coated substrates [42, 43] or cells [44] was
established previously. In this study, by exposing FimH-
expressing E. coli under shear stress conditions to endothelial
cells seeded onto biochips, we identified potential novel ef-
fects of FimH mutations.
We established two assays that enabled us to compare
adhesion to pure mannosylated substrates and relevant
urothelial and endothelial cells under static and shear stress
conditions: in the first assay, similar to a recently described
method [38], we allowed FimH-bearing E. coli to adhere to
mammalian cells under static conditions and analysed the
numbers of bacteria attached by FACS. The second assay
measured the adherence under shear stress by allowing
bacteria to bind 1 M or 3 M substrates and cells under flow.
We found that the results between static assays that mea-
sure adhesion to mannosylated substrates or mammalian
cells correlated well. But there were distinct differences
when we compared the results of wild-type or mutated
FimH-bearing E. coli adhering to cells under static condi-
tions to those under shear stress conditions.
FimH mediates the adhesion of E. coli to brain endothelial
cells and is a virulence factor critical for blood-borne dissem-
ination of E. coli [4]. We show that FimH also mediates effi-
cient bacterial adhesion to human microvascular endothelium
of the skin and the glomerulus of the kidney under static
conditions and during physiological shear stress. In agreement
with other studies, bacteria adhered better under conditions of
high shear stress (1 dyne/cm2), which reflects the physiolog-
ical condition [40], than low shear stress (0.2 dyne/cm2) [7,
44]. Once attached, adherent bacteria could not be dislodged.
It is known that shear stress enhances the strength of FimH-
mediated adhesion through allosteric coupling [41, 45, 46],
which could contribute to the failure of shear stress to dislodge
adherent MSC95-FimH. The high affinity binding of terminal
mannose residues on cellular receptors to MBP of FimH is the
central event in E. coli adhesion.
Our panel of E. coli MSC95-FimH strains with unique
FimH mutations enabled us to identify, in addition to those
described [10], amino acids that differentially modulated the
effect of shear stress. The ability of FimH mutations to disrupt
fimbriogenesis is a potential limitation to this approach [33]
that affected three of our strains.Wemeasured the agglutination
potential of these mutant strains and found that they correlated
relatively well with other reports [31]. Minor differences could
lie in the glycosylation of guinea pig red blood cells compared
to yeast, as reported by others [47–49]. Regardless, the results
with the remaining nine strains with normal fimbriae demon-
strated that the mannose binding pocket is crucial for the adhe-
sion ofE. coli to endothelial cells [31]. Comparison of adhesion
to endothelium under static and shear stress conditions revealed
that E50 and T53 were essential under shear stress. This only
partly correlated with binding to mannosylated substrates under
identical assay conditions, demonstrating that there are impor-
tant differences for the adhesion of isolated mannosylated sub-
strates and mammalian cells. E50 has been demonstrated to not
interact with the sugar ligand, but to stabilise R98, which is,
thereby, oriented to interact with the ligand [50]. Due to its
location on the backbone of the MBP, T53 interactions with
3-mannose are blocked by the side chains of I52 and D54. The
effect of T53 mutations can, therefore, only be indirect through
changes in its backbone energetic minimum, which could lead
to gentle changes in the 3-mannose binding site [27, 50]. This
supports a model in which these amino acid residues contribute
to initial interaction between FimH and its cellular receptors,
and that facilitates subsequent insertion of their terminal man-
nose residues into the MBP to establish firm adhesion. This
would be consistent with the lack of reportedmutations of these
residues in clinical E. coli isolates, suggesting an important
evolutionary conserved contribution to virulence [51].
The E. coli strain MSC95-FimH adhered efficiently to mi-
crovascular endothelium both under static conditions and
shear stress, whereas adhesion to all three urothelial cell lines
tested in static conditions was less efficient and appeared ab-
rogated by flow. The observation that MSC95-FimH fails to
adhere to bladder epithelial cells under flow is in apparent
contrast to an earlier study [44]. However, the discrepancy
probably relates to technical differences between the two stud-
ies and specifically to our use of an E. coli strain specifically
engineered to express type 1 fimbriae exclusively, which en-
abled us to examine the unique effects of FimH.
In our experiments, differences between FimH-mediated ad-
hesion to urothelial cells under static and shear stress conditions
could be regarded, as the experimental results correlate
stop/flow conditions that occur in the urinary bladder during
voiding. Allowing MSC95-FimH to adhere under static condi-
tions before applying shear stress resulted in an increase of bac-
teria bound to the non-neoplastic urothelial cell line SV-HUC
Eur J Clin Microbiol Infect Dis
and, to a lesser extent, to the neoplastic cell lines 5637 and
HT1376 that were not dislodged by flow. Using this setup, we
confirmed the reduced adhesion capabilities of E50A and T53A,
although the effect was less obvious than during continuous
flow. This supports the model in which these residues contribute
to mannose binding. When mutated, FimH is limited in making
contact with mannose residues under shear stress conditions.
In summary, we show that, by analysing bacterial adhesion
under physiologically relevant conditions, novel effects of
FimH mutations are observed. Our study thus highlights the
fact that the results obtained from investigating FimH adhe-
sion are dependent on the methodological differences of the
assays used and the physiological situation they represent. The
results with MSC95-FimH, expressing native or mutated var-
iants of FimH, identified the importance of the MBP that
critically influences the adhesion under flow, and provide nov-
el insights into screening methods to determine the effect of
FimH mutants and potentially FimH antagonists.
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